Thus, the combinative treatment with anti-CTLA-4 plus anti-PD-1 or anti-PD-L1 should lead to the creation of an immunogenic tumor microenvironment with clinical benefits for patients regardless of their tumor original PD-L1 expression levels. The gene discussed is PDCD1; the disease is neoplasm.